Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression

Cancer Letters

Volumn 282, Issue 1, 2009, Pages 14-24

  Mukohara, Toru ^a   Shimada, Hiroyuki ^a   Ogasawara, Naomi ^a   Wanikawa, Ryoko ^a   Shimomura, Manami ^a   Nakatsura, Tetsuya ^a   Ishii, Genichiro ^a   Park, Joon Oh ^b,c   Jänne, Pasi A ^c   Saijo, Nagahiro ^a   Minami, Hironobu ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b Samsung Medical Center   (South Korea)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; IGF 1R; IRS 1; Tyrosine kinase inhibitor

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; NAVELBINE; NVP AEW 541; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1;

EID: 67649628084     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.056     Document Type: Article

References (34)

1. McPherson K., Steel C.M., and Dixon J.M. ABC of breast diseases, breast cancer-epidemiology, risk factors, and genetics. BMJ 321 (2000) 624-628
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
3. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl. J. Med. 344 (2001) 783-792
4. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., and Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl. J. Med. 353 (2005) 1659-1672
5. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., and Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl. J. Med. 353 (2005) 1673-1684
6. Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., Pusztai L., Green M.C., Arun B.K., Giordano S.H., Cristofanilli M., Frye D.K., Smith T.L., Hunt K.K., Singletary S.E., Sahin A.A., Ewer M.S., Buchholz T.A., Berry D., and Hortobagyi G.N. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 23 (2005) 3676-3685
7. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. New Engl. J. Med. 353 (2005) 172-187
8. Ibrahim Y.H., and Yee D. Insulin-like growth factor-I and breast cancer therapy. Clin. Cancer. Res. 11 (2005) 944s-950s
9. Feng Y., Zhu Z., Xiao X., Choudhry V., Barrett J.C., and Dimitrov D.S. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol. Cancer Ther. 5 (2006) 114-120
10. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4 (2004) 505-518
11. Jackson J.G., White M.F., and Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J. Biol. Chem. 273 (1998) 9994-10003
12. Dillon R.L., White D.E., and Muller W.J. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26 (2007) 1338-1345
13. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., Riggs B.L., Horvath S., Liau L.M., Cavenee W.K., Rao P.N., Beroukhim R., Peck T.C., Lee J.C., Sellers W.R., Stokoe D., Prados M., Cloughesy T.F., Sawyers C.L., and Mischel P.S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. New Engl. J. Med. 353 (2005) 2012-2024
14. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., Hortobagyi G.N., Hung M.C., and Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 (2004) 117-127
15. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., Beijersbergen R.L., Mills G.B., van de Vijver M.J., and Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12 (2007) 395-402
16. Shimizu C., Hasegawa T., Tani Y., Takahashi F., Takeuchi M., Watanabe T., Ando M., Katsumata N., and Fujiwara Y. Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum. Pathol. 35 (2004) 1537-1542
17. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., Rosner B., Speizer F.E., and Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 (1998) 1393-1396
18. Chang Q., Li Y., White M.F., Fletcher J.A., and Xiao S. Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res. 62 (2002) 6035-6038
19. Rocha R.L., Hilsenbeck S.G., Jackson J.G., VanDenBerg C.L., Weng C., Lee A.V., and Yee D. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin. Cancer Res. 3 (1997) 103-109
20. Lu Y., Zi X., Zhao Y., Mascarenhas D., and Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 93 (2001) 1852-1857
21. Scotlandi K., Manara M.C., Nicoletti G., Lollini P.L., Lukas S., Benini S., Croci S., Perdichizzi S., Zambelli D., Serra M., Garcia-Echeverria C., Hofmann F., and Picci P. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer. Res. 65 (2005) 3868-3876
22. Garcia-Echeverria C., Pearson M.A., Marti A., Meyer T., Mestan J., Zimmermann J., Gao J., Brueggen J., Capraro H.G., Cozens R., Evans D.B., Fabbro D., Furet P., Porta D.G., Liebetanz J., Martiny-Baron G., Ruetz S., and Hofmann F. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5 (2004) 231-239
23. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., Cichowski K., Johnson B.E., and Cantley L.C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 102 (2005) 3788-3793
24. Mukohara T., Civiello G., Davis I.J., Taffaro M.L., Christensen J., Fisher D.E., Johnson B.E., and Janne P.A. Inhibition of the met receptor in mesothelioma. Clin. Cancer Res. 11 (2005) 8122-8130
25. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
26. Lacroix M., and Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 83 (2004) 249-289
27. Hanada M., Feng J., and Hemmings B.A. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim. Biophys. Acta 1697 (2004) 3-16
28. Byron S.A., Horwitz K.B., Richer J.K., Lange C.A., Zhang X., and Yee D. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br. J. Cancer 95 (2006) 1220-1228
29. Koda M., Sulkowska M., Kanczuga-Koda L., and Sulkowski S. Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases. J. Clin. Pathol. 58 (2005) 645-649
30. Saal L.H., Holm K., Maurer M., Memeo L., Su T., Wang X., Yu J.S., Malmstrom P.O., Mansukhani M., Enoksson J., Hibshoosh H., Borg A., and Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65 (2005) 2554-2559
31. Isakoff S.J., Engelman J.A., Irie H.Y., Luo J., Brachmann S.M., Pearline R.V., Cantley L.C., and Brugge J.S. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 65 (2005) 10992-11000
32. Guerreiro A.S., Boller D., Shalaby T., Grotzer M.A., and Arcaro A. Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition. Int. J. Cancer 119 (2006) 2527-2538
33. Bjorndahl M., Cao R., Nissen L.J., Clasper S., Johnson L.A., Xue Y., Zhou Z., Jackson D., Hansen A.J., and Cao Y. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc. Natl. Acad. Sci. USA 102 (2005) 15593-15598
34. Tanno B., Mancini C., Vitali R., Mancuso M., McDowell H.P., Dominici C., and Raschella G. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin. Cancer Res. 12 (2006) 6772-6780